JAZZ Stock Overview
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Jazz Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$109.94 |
| 52 Week High | US$146.70 |
| 52 Week Low | US$106.61 |
| Beta | 0.61 |
| 1 Month Change | -11.90% |
| 3 Month Change | -5.66% |
| 1 Year Change | -24.36% |
| 3 Year Change | -34.06% |
| 5 Year Change | -16.07% |
| Change since IPO | 520.08% |
Recent News & Updates
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price
Apr 02
Recent updates
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price
Apr 02Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Updated View On Jazz Pharmaceuticals' 2025 Goals
Jan 29Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking
Dec 26Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market
Aug 24Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy
Aug 18Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Aug 10Jazz Pharmaceuticals: Strong Launch Of Xywav In Idiopathic Hypersomnia
Jun 08Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt
May 12Jazz Pharmaceuticals: Imminent Danger With A Worrying History
Feb 04Shareholder Returns
| JAZZ | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.6% | -2.3% | -3.7% |
| 1Y | -24.4% | 11.4% | 20.2% |
Return vs Industry: JAZZ underperformed the US Pharmaceuticals industry which returned 11.4% over the past year.
Return vs Market: JAZZ underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| JAZZ volatility | |
|---|---|
| JAZZ Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: JAZZ has not had significant price volatility in the past 3 months.
Volatility Over Time: JAZZ's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,800 | Bruce Cozadd | www.jazzpharma.com |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders.
Jazz Pharmaceuticals plc Fundamentals Summary
| JAZZ fundamental statistics | |
|---|---|
| Market cap | US$6.81b |
| Earnings (TTM) | US$414.83m |
| Revenue (TTM) | US$3.83b |
16.5x
P/E Ratio1.8x
P/S RatioIs JAZZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JAZZ income statement (TTM) | |
|---|---|
| Revenue | US$3.83b |
| Cost of Revenue | US$284.13m |
| Gross Profit | US$3.55b |
| Other Expenses | US$3.14b |
| Earnings | US$414.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 6.65 |
| Gross Margin | 92.59% |
| Net Profit Margin | 10.82% |
| Debt/Equity Ratio | 153.0% |
How did JAZZ perform over the long term?
See historical performance and comparison